Literature DB >> 25809545

National Healthcare Delivery Systems Influence Lung Transplant Outcomes for Cystic Fibrosis.

C A Merlo1,2, S C Clark3, G J Arnaoutakis4, N Yonan5, D Thomas6, A Simon7, R Thompson8, H Thomas8, J Orens1, A S Shah4.   

Abstract

Successful lung transplantation (LTx) depends on multiple components of healthcare delivery and performance. Therefore, we conducted an international registry analysis to compare post-LTx outcomes for cystic fibrosis (CF) patients using the UNOS registry in the United States and the National Health Service (NHS) Transplant Registry in the United Kingdom. Patients with CF who underwent lung or heart-lung transplantation in the United States or United Kingdom between January 1, 2000 and December 31, 2011 were included. The primary outcome was all-cause mortality. Kaplan-Meier analysis and Cox proportional hazards regression evaluated the effect of healthcare system and insurance on mortality after LTx. 2,307 US LTx recipients and 451 individuals in the United Kingdom were included. 894 (38.8%) US LTx recipients had publically funded Medicare/Medicaid insurance. US private insurance and UK patients had improved median predicted survival compared with US Medicare/Medicaid recipients (p < 0.001). In multivariable Cox regression, US Medicare/Medicaid insurance was associated with worse survival after LTx (US private: HR0.78,0.68-0.90,p = 0.001 and UK: HR0.63,0.41-0.97, p = 0.03). This study in CF patients is the largest comparison of LTx in two unique health systems. Both the United States and United Kingdom have similar early survival outcomes, suggesting important dissemination of best practices internationally. However, the performance of US public insurance is significantly worse and may put patients at risk. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research / practice; epidemiology; health services and outcomes research; insurance; lung transplantation / pulmonology; organ transplantation in general; quality of care / care delivery

Mesh:

Year:  2015        PMID: 25809545     DOI: 10.1111/ajt.13226

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  6 in total

Review 1.  Unmet needs in cystic fibrosis: the next steps in improving outcomes.

Authors:  Natalie E West; Patrick A Flume
Journal:  Expert Rev Respir Med       Date:  2018-06-19       Impact factor: 3.772

2.  Clinical characteristics of cystic fibrosis patients prior to lung transplantation: An international comparison between Canada and the United States.

Authors:  Bradley S Quon; Jenna Sykes; Sanja Stanojevic; Bruce C Marshall; Kristofer Petren; Josh Ostrenga; Aliza Fink; Alexander Elbert; Albert Faro; Christopher H Goss; Anne L Stephenson
Journal:  Clin Transplant       Date:  2018-02-11       Impact factor: 2.863

Review 3.  Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies.

Authors:  Gabriela R Oates; Michael S Schechter
Journal:  Expert Rev Respir Med       Date:  2022-06-23       Impact factor: 4.300

4.  Increased Mortality in Adult Cystic Fibrosis Patients with Medicaid Insurance Awaiting Lung Transplantation.

Authors:  Katelyn Krivchenia; Dmitry Tumin; Joseph D Tobias; Don Hayes
Journal:  Lung       Date:  2016-08-10       Impact factor: 2.584

5.  Survival Comparison of Patients With Cystic Fibrosis in Canada and the United States: A Population-Based Cohort Study.

Authors:  Anne L Stephenson; Jenna Sykes; Sanja Stanojevic; Bradley S Quon; Bruce C Marshall; Kristofer Petren; Josh Ostrenga; Aliza K Fink; Alexander Elbert; Christopher H Goss
Journal:  Ann Intern Med       Date:  2017-03-14       Impact factor: 25.391

6.  Survival and Lung Transplant Outcomes for Individuals With Advanced Cystic Fibrosis Lung Disease Living in the United States and Canada: An Analysis of National Registries.

Authors:  Kathleen J Ramos; Jenna Sykes; Sanja Stanojevic; Xiayi Ma; Joshua S Ostrenga; Aliza Fink; Bradley S Quon; Bruce C Marshall; Albert Faro; Kristofer Petren; Alexander Elbert; Christopher H Goss; Anne L Stephenson
Journal:  Chest       Date:  2021-04-17       Impact factor: 10.262

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.